Send to

Choose Destination
Mult Scler J Exp Transl Clin. 2018 Jul 17;4(3):2055217318787829. doi: 10.1177/2055217318787829. eCollection 2018 Jul-Sep.

MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response.

Author information

Department of Neurology, Nitte University, India.
Department of Neurology, Tohoku University Graduate School of Medicine, Japan.



We investigated the clinical characteristics and treatment response in myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease and looked for evidence of subclinical disease.


We prospectively evaluated the frequency and pattern of relapse, tested afferent visual function and monitored treatment response in 42 south Asian patients from a single centre.


Eighteen patients (42.9%) had monophasic and 24 (57.1%) a relapsing course. Disease duration was longer (P<0.02) in those with a relapsing course. Median time to the second attack was prolonged (P<0.04) in patients with recurrent transverse myelitis when compared with neuromyelitis optica spectrum disorder and recurrent optic neuritis. Thirteen out of 17 patients (76.5%) initially presenting with optic neuritis developed recurrent optic neuritis later. After the first attack of transverse myelitis, 17 out of 22 (77.3%) had disease confined to the spinal cord. Optical coherence tomography detected peripapillary retinal nerve fibre layer thickness (P<0.05) and macular ganglion cell complex volume (P<0.005) abnormalities in seven out of 10 (70.0%) patients without clinical optic neuritis. Immunosuppressants induced remission in 17 out of 22 (77.3%) patients during a median follow-up of 48 months and the median Expanded Disability Status Score was 1 (range 1-10).


Our study highlighted the tendency for stereotypical attacks in MOG-IgG-associated disease, heterogeneity in clinical course among subtypes, subclinical visual impairment and the need for early and sustained immunosuppressive therapy.


Demyelinating disorders; South India; anti-MOG-IgG; disease heterogeneity; subclinical visual loss

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center